key: cord-0749199-00udpo5k authors: Kato, Kiyoko; Inoue, Eiko; Tanaka, Sakae; Kawamoto, Hiroshi title: Increase in the incidence of acute inflammatory reactions to injectable fillers during COVID‐19 era date: 2022-03-12 journal: J Cosmet Dermatol DOI: 10.1111/jocd.14886 sha: 103844db563613d645f416aa3cc6734b315dc0ab doc_id: 749199 cord_uid: 00udpo5k BACKGROUND: Acute inflammatory reactions (AIRs) are a rare complication following esthetic treatment with hyaluronic acid (HA) and/or human collagen fillers. However, a substantial increase in the frequency of AIRs was observed in the first author's clinic since May 2020. AIMS: To report AIR cases, we experienced and discuss potential underlying mechanisms. METHODS: This was a retrospective review of patients representing AIR symptoms following filler injection with HA or human collagen in our clinic. RESULTS: Although only one case of an AIR with an incidence rate of 0.01% was recorded following filler treatment between September 2008 and April 2020 in our clinic, we observed 14 AIR cases without anaphylaxis, with an incidence rate of 1.18% between May 2020 and June 2021, in line with the spreading of the new coronavirus pandemic. All cases were females aged 40–57 years, and the time of onset was within hours after filler injection. Three patients had been treated with HA fillers only, 2 with HA plus human collagen, and 9 with human collagen only. Most patients had been treated with these products in the past. Nine patients were treated with oral prednisolone. In all cases, symptoms resolved entirely within a week without sequelae. CONCLUSIONS: The marked increase in AIRs coincided with the COVID‐19 pandemic. Possible explanations include immune system alterations caused by extensive changes in domestic and personal hygiene, prolonged and elevated stress levels, and subclinical COVID‐19 infection. Further studies may be warranted. Nonetheless, there are potential complications. Bruising, temporary erythema, and local pain are relatively common, while less frequent AEs include vascular occlusion (estimated incidence rate: 0.05%), 3 delayed inflammatory reactions (DIRs; 0.02%-4.25%), 4, 5 and acute inflammatory reactions (AIRs). AIRs are extremely rare AEs, manifesting as localized redness, swelling, edema, heat, pain, and nodules occurring within minutes to hours after injection. In our clinic, only one case of an AIR was recorded following filler treatment in the 12 years between September 2008 and April 2020, with an incidence rate of 0.01%. However, we have observed a marked increase in the frequency of AIRs since May 2020, in line with the spreading of the new coronavirus pandemic. The purpose of this report is to describe these cases and to discuss potential mechanisms underlying them. This was a retrospective analysis of patients experiencing an AIR following filler injection with HA or human collagen in the first author's clinic. The assessment was conducted in accordance with the Declaration of Helsinki, and all patients provided informed consent for treatment. All filler treatments during the study period used one or more the following products: the Vycross range of HA fillers (VYC- and/or the human collagen product, Humallagen (Cosmetic Medicine Enterprises Inc.). Injections were mostly performed using a cannula, except when giving injections onto the bone (e.g., zygomatic arch or temporalis), which were delivered using a sharp needle. Fifteen minutes before commencing treatment, an anesthetic cream was applied containing 9.6% lidocaine; in addition, 0.025% (w/v) benzalkonium chloride solution was used for skin preparation. For patients treated in the tear trough area with HA, or given four or more HAs, oral prednisolone (PSL) 10 mg was prescribed for use on the same day of treatment. If swelling occurred on the following day, patients were instructed to take another 5 mg of PSL. There is no well-recognized, standardized definition of AIR, and we defined it as local inflammatory reaction characterized by features such as redness, swelling, edema, heat, pain, and/or nodules that occurred within minutes to hours after filler injection in this study. One individual who developed an AIR that led to an anaphylactic reaction was excluded in the present analysis. A total of 14 cases of AIRs (without anaphylaxis) were recorded between May 2020 and June 2021 (Table 1; Figure 1 ). Since 1,180 patients were treated with fillers over the study period, this equates to an incidence rate of 1.18%. 1,020 patients received HA filler and 882 received human collagen (Humallagen), 722 patients having undergone both procedures. All cases that developed AIRs were females aged 40-57 years, and the time of onset was between a few minutes and a few hours after filler injection. Three patients had been treated only with an HA filler (n = 2, Vycross; n = 1, Belotero); two patients had received combination therapy with human collagen (Humallagen) plus an HA filler (Vycross), and nine individuals had received a human collagen filler only (Humallagen) ( Table 2) . Cases 1, 2, and 8 received HA alone (Table 1) , two receiving it for the first time to treat tear trough depression and forehead, and one undergoing a second round of treatment in the cheek and perioral area. Cases 4 and 11 had received combination treatment for tear trough depression using HA and human collagen, and in both cases the HA filler had been used for the first time; case 4 had also received human collagen for the first time, but case 11 had received several injections of collagen before. Simultaneous use of HA and human collagen is common in treating tear trough depression when mid-cheek volumization is also needed. In the 9 cases of AIR following human collagen use alone, 8 had undergone treatment for tear trough depression and 1 for neck wrinkles; all 9 of these patients had received at least two previous rounds of collagen injection, several months apart, but they never experienced AIR before. Among the 11 patients who received human collagen (alone or in combination), the volume used was between 0.5 and 1.0 ml, which is the usual quantity in our practice. With regard to collagen, products of bovine origin were once widely utilized. However, since they caused high rates of allergic reaction (3%-5%), 9,10 they were gradually replaced by human collagen. Human tissue-derived CosmoDerm (Inamed) was extensively used for a short period, due to its low allergy incidence and the lack of requirement for prior allergy testing. It was approved by the US FDA in 2003 and was marketed until 2010, with only two cases of AIR reported during that period. 11 Nonetheless, CosmoDerm was ultimately discontinued, owing to its high cost and short duration of efficacy. After that, long-lasting HA products emerged, and human collagen is now available only in Japan (Humallagen) and Korea (Bellacol [Hans Biomed]). 12 The incidence rates of allergy with these products are very low, and to the best of our knowledge, no cases of AIRs have been previously reported. pandemic were 70%-80% lower compared with previous years. [13] [14] [15] In 1989, Strachan investigated the environmental factors associated with the development of allergic diseases and proposed that there were important differences in the frequency of exposure to infection during infancy, which became the basis for the "hygiene hypothesis." 16 This idea was later developed in a variety of ways. It has been suggested that during the differentiation of naïve T cells into Th1 and Th2 cells in the neonatal period, exposure to bacteria and viruses induces greater differentiation to Th1 cells-whereas in a more sterile environment this differentiation is Th2-dominant and individuals have increased susceptibility to allergy. 17 More recently, the potential impact of symbiotic intestinal microflora and parasitic helminths has been added to this hypothesis 18 ; during microflora development in childhood, a hyper-hygienic environment may reduce the diversity of these organisms and thus induce immune diseases. F I G U R E 1 Acute inflammatory reactions. Images were taken by patients within a few hours of filler treatment: case 5 (a 44-year-old woman given 0.5 ml of Humallagen for tear trough depression; part A), case 6 (a 53-year-old woman given 0.5 ml of Humallagen for tear trough depression; part B) The gut microflora is formed in childhood but can change in adult life according to various factors, including diet, environment, and stress. 19 Some experts have warned that hygiene changes associated with the COVID-19 pandemic could affect the microflora and alter human immune systems, particularly in high-resource countries. 20 It is possible that HA and human collagen were not previously significantly allergenic due to their high biocompatibility, but have recently become more so due to immune system changes caused by an ultrahygienic environment, thereby leading to AIRs. The cases reported here came from various backgrounds, but like most Japanese people, they all complied with advice to wear face masks, wash their hands frequently, and disinfect with alcohol during the pandemic. Most of our AIR patients had been treated with human collagen. We routinely prescribe PSL 10 mg/day to all individuals receiving HA injections in order to prevent the risk of DIRs; however, PSL was not given to patients receiving human collagen because there were no previous reports of DIRs with this type of filler. That could explain the higher incidence of AIRs in patients using human collagen versus HA. Indeed, the three cases of AIRs who had received HA alone refused prophylactic PSL. This suggests that the prophylactic corticosteroid use may be recommended in patients receiving filler to mitigate the risk of AIRs. It is also noteworthy that most AIRs were in patients treated for tear trough depression. However, this is not surprising given that over 80% of individuals at our center receive human collagen for this indication. In addition, the deep fat compartment, which is injected during the treatment of tear trough depression, is an enclosed space that does not allow lymphatic drainage and is, therefore, highly symptom-inducing. We acknowledge the limitations of this study. First, it reports only cases at one clinic, and most were related to a single product (human collagen) that is not widely used outside Japan and Korea. Nonetheless, the increase in AIRs was both highly pronounced and not limited entirely to collagen. Second, the background of the patients was not uniform and PSL was given prophylactically only to patients receiving HA. However, even taking into account these limitations, it is striking that there was such a large increase in the incidence of AIRs coinciding with the COVID-19 pandemic. We have observed a marked increase in cases of acute hypersensitivity reactions to injectable treatment with collagen and/or HA fillers since the beginning of the COVID-19 pandemic, and such adverse events were rarely observed before the pandemic. A larger, multicenter study is required to demonstrate the relationship with COVID-19 in more detail. We thank Dr Akiko Nomura and Dr Timothy Ryder for their help in refining the English in this paper. The authors report no conflicts of interest to disclose. The authors confirm that the ethical policies of the journal, as noted on the journal's author guidelines page, have been adhered to. The data that support the findings of this study are available from the corresponding author upon reasonable request. Vascular compromise from soft tissue augmentation: experience with 12 cases and recommendations for optimal outcomes Late-onset inflammatory response to hyaluronic acid dermal fillers Delayed inflammatory reactions to hyaluronic acid fillers: a literature review and proposed treatment algorithm Angioedema acute hypersensitivity reaction to injectable hyaluronic acid A severe acute hypersensitivity reaction after a hyaluronic acid with lidocaine filler injection to the lip Evaluation of the safety of a non-animal stabilized hyaluronic acid (NASHA-Q-Medical, Sweden) in European countries: a retrospective study from 1997 to Adverse reactions to dermal fillers: a review of European experiences Complications of collagen fillers Human collagen reactions Comparative evaluation of the biodegradability and wrinkle reduction efficacy of humanderived collagen filler and hyaluronic acid filler The disappearance of respiratory viruses in children during the COVID-19 pandemic Decreased influenza incidence under COVID-19 control measures Collateral benefit of COVID-19 control measures influenza activity Hay fever, hygiene, and household size The effect of infections on susceptibility to autoimmune and allergic diseases The hygiene hypothesis: current perspectives and future therapies The gut microbiome: what we do and don't know The hygiene hypothesis, the COVID pandemic, and consequences for the human microbiome Differential expression of the beta2-adrenergic receptor by Th1 and Th2 clones: implications for cytokine production of B cell help The beta2-adrenergic receptor on T and B lymphocytes: do we understand it yet? Corticosteroids enhance the capacity of macrophages to induce Th2 cytokine synthesis in CD4+ lymphocytes by inhibiting IL-12 production The impact of psychological stress on mast cells Delayed-onset nodules secondary to a smooth cohesive 20mg/ml hyaluronic acid filler: cause and management Delayed hypersensitivity reaction to hyaluronic acid dermal filler following influenza-like illness COVID-19: Immunology and treatment options Belotero Soft Lidocaine. Instructions for use Juvéderm Vollure XC. Directions for use Juvéderm Voluma XC. Directions for use